[go: up one dir, main page]

YU6401A - Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene - Google Patents

Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene

Info

Publication number
YU6401A
YU6401A YU6401A YU6401A YU6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A YU 6401 A YU6401 A YU 6401A
Authority
YU
Yugoslavia
Prior art keywords
eletryptane
medicine
prevention
production
application
Prior art date
Application number
YU6401A
Other languages
English (en)
Inventor
Neville Colin Jackson
Stephen Uden
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to YU20303A priority Critical patent/YU20303A/sh
Publication of YU6401A publication Critical patent/YU6401A/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Pronalazak se odnosi na primenu eletriptana, ili neke njegove farmaceutski prihvatljive soli iil kompozicije, na proizvodnju medikamenta za sprečavanje ponovnog javljanja migrene i na primenu jednog agonista 5-HT18/1D receptora, ili neke njegove farmaceutski prihvatljive soli ili kompozicije, za proizvodnju farmaceutske kompozicije sa dvostrukim, zadržanim, odloženim, konrolisanim ili pulsirajućim ispuštanjem za sprečavanje ponovnog javljanja migrene.
YU6401A 1998-07-30 1999-06-14 Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene YU6401A (sh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy

Publications (1)

Publication Number Publication Date
YU6401A true YU6401A (sh) 2004-03-12

Family

ID=10836395

Family Applications (2)

Application Number Title Priority Date Filing Date
YU6401A YU6401A (sh) 1998-07-30 1999-06-14 Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene

Family Applications After (1)

Application Number Title Priority Date Filing Date
YU20303A YU20303A (sh) 1998-07-30 1999-06-14 Farmaceutski preparat za prevenciju učestanog javljanja migrene

Country Status (36)

Country Link
EP (3) EP1100499B1 (sh)
JP (1) JP3824863B2 (sh)
KR (2) KR100441732B1 (sh)
CN (2) CN1155379C (sh)
AP (1) AP1402A (sh)
AT (1) ATE261304T1 (sh)
AU (1) AU3952199A (sh)
BG (1) BG65309B1 (sh)
BR (1) BR9912588A (sh)
CA (1) CA2338901C (sh)
CZ (1) CZ2001357A3 (sh)
DE (1) DE69915486T2 (sh)
DK (1) DK1100499T3 (sh)
EA (2) EA200201149A1 (sh)
EE (1) EE04703B1 (sh)
ES (1) ES2214027T3 (sh)
GB (1) GB9816556D0 (sh)
GE (2) GEP20043157B (sh)
HK (1) HK1038198A1 (sh)
HR (1) HRP20010079A2 (sh)
HU (1) HUP0103424A3 (sh)
ID (1) ID26996A (sh)
IL (1) IL140169A0 (sh)
IS (1) IS2253B (sh)
NO (1) NO20010489L (sh)
NZ (2) NZ508736A (sh)
OA (1) OA11576A (sh)
PL (1) PL194611B1 (sh)
PT (1) PT1100499E (sh)
SG (1) SG125910A1 (sh)
SK (1) SK1182001A3 (sh)
TR (1) TR200100314T2 (sh)
TW (2) TWI248362B (sh)
UA (1) UA76399C2 (sh)
WO (1) WO2000006161A1 (sh)
YU (2) YU6401A (sh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
US7332183B2 (en) * 2002-12-26 2008-02-19 Pozen Inc. Multilayer dosage forms containing NSAIDs and triptans
EP1615635A1 (en) 2003-04-11 2006-01-18 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
CA2765866C (en) 2008-06-20 2016-06-21 Alphapharm Pty Ltd Single phase pharmaceutical composition of a 5-ht1 inhibitor and an nsaid
EP2490669B1 (en) 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
MY169068A (en) * 2012-04-18 2019-02-12 Contera Pharma Aps Orally available pharmaceutical formulation suitable for improved management of movement disorders
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
US11975104B2 (en) 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2575272B2 (ja) * 1990-10-15 1997-01-22 フアイザー・インコーポレイテツド インドール誘導体
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
ID24528A (id) * 1997-07-03 2000-07-20 Pfizer Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Also Published As

Publication number Publication date
IL140169A0 (en) 2002-02-10
EP1466601A3 (en) 2005-04-13
EA200100089A1 (ru) 2001-08-27
JP2002521446A (ja) 2002-07-16
PT1100499E (pt) 2004-06-30
PL194611B1 (pl) 2007-06-29
BG65309B1 (bg) 2008-01-31
DE69915486T2 (de) 2005-03-03
HUP0103424A2 (hu) 2002-02-28
BG105277A (en) 2001-11-30
TW537893B (en) 2003-06-21
HK1038198A1 (en) 2002-03-08
EP1100499A1 (en) 2001-05-23
KR100441732B1 (ko) 2004-07-27
CN1522697A (zh) 2004-08-25
TWI248362B (en) 2006-02-01
CA2338901A1 (en) 2000-02-10
NZ508736A (en) 2003-09-26
HUP0103424A3 (en) 2003-05-28
KR20030078876A (ko) 2003-10-08
YU20303A (sh) 2006-08-17
AU3952199A (en) 2000-02-21
NO20010489L (no) 2001-03-26
JP3824863B2 (ja) 2006-09-20
EE200100061A (et) 2002-06-17
SG125910A1 (en) 2006-10-30
EP1435237A1 (en) 2004-07-07
TW200300674A (en) 2003-06-16
ID26996A (id) 2001-02-22
DE69915486D1 (de) 2004-04-15
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
IS5771A (is) 2000-12-15
CN1309560A (zh) 2001-08-22
DK1100499T3 (da) 2004-06-14
PL345803A1 (en) 2002-01-02
WO2000006161A1 (en) 2000-02-10
OA11576A (en) 2004-07-01
GEP20043157B (en) 2004-01-26
ES2214027T3 (es) 2004-09-01
UA76399C2 (en) 2006-08-15
BR9912588A (pt) 2001-05-02
EA004036B1 (ru) 2003-12-25
TR200100314T2 (tr) 2001-06-21
CA2338901C (en) 2008-02-19
EP1100499B1 (en) 2004-03-10
IS2253B (is) 2007-06-15
HRP20010079A2 (en) 2002-02-28
GEP20063719B (en) 2006-01-10
KR20010079582A (ko) 2001-08-22
NO20010489D0 (no) 2001-01-29
CN1155379C (zh) 2004-06-30
NZ527625A (en) 2005-01-28
EE04703B1 (et) 2006-10-16
EP1466601A2 (en) 2004-10-13
CZ2001357A3 (cs) 2001-10-17
SK1182001A3 (en) 2001-10-08
EA200201149A1 (ru) 2003-02-27
AP1402A (en) 2005-04-29
GB9816556D0 (en) 1998-09-30

Similar Documents

Publication Publication Date Title
YU6401A (sh) Primena eletriptana za izradu leka za prevenciju učestanog javljanja migrene
IS1892B (is) Nýjar samsetningar virkra efna sem innihalda klópidógrel og andþrombín
IT1276689B1 (it) Forma farmaceutica solida ad uso orale
RS50377B (sr) Inhibitori sistema renin-angiotenzin i njihova primena
YU48600A (sh) Celekoksibne smese
RS50091B (sr) Upotreba retigabina u lečenju neuropatskog bola
MXPA05005895A (es) Composicion farmaceutica de 1-(3, 4-dimetoxifenil)-4 -metil-5-etil -7-metoxi-8 -hidroxi- 5h-2, 3-benzodiacepina y usos de la misma.
BRPI0412557A (pt) forma de dosagem farmacêutica de eventos cardiovasculares
YU92501A (sh) Levodop/karbidop/entakapon farmaceutski preparat
BG105857A (en) Pregelatinized starch in a controlled release formulation
AU1729397A (en) Process to prepare soluble delivery systems using volatile salts
MY135852A (en) Pharmaceutical products
MXPA02006151A (es) Composiciones de liberacion dual de un inhibidor de ciclooxigenasa-2.
RS50303B (sr) Farmaceutska kompozicija nimesulida sa kontrolisanim oslobađanjem
ID28510A (id) Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
AR012247A1 (es) Composiciones farmaceuticas y su uso para la preparacion de medicamentos destinados a prevenir y tratar las enfermedades tromboembolicas arteriales
ATE287264T1 (de) Oral anzuwendende buprenorphinhaltige arzneimittel
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
MXPA06002722A (es) Composicion farmaceutica que comprende un antagonista del receptor p2x7 y un farmaco anti-inflamatorio no esteroidal.
MA27102A1 (fr) Composition pharmaceutique orodispersible d'ivabradine
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
MA27099A1 (fr) Composition pharmaceutique orodispersible de perindopril
EA200200914A1 (ru) Система контроля дозирования для однократного ежедневного приема назначенного ципрофлоксацина
MXPA05005893A (es) Composicion farmaceutica de 1-(3-hidroxi -4-metoxifenil) -4-metil-5 -etil-7, 8-dimetoxi- 5h-2, 3-benzodiazepina y usos de la misma.
YU87501A (sh) Farmaceutski kompleksi